A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 13 Jul 2017 Planned End Date changed from 17 Aug 2018 to 7 Sep 2018.
- 13 Jul 2017 Planned primary completion date changed from 17 Aug 2018 to 7 Sep 2018.
- 10 Jun 2017 Biomarkers information updated